We’re gearing up for the World Orphan Drug Congress Europe 2025 with the theme: “Where technology meets Human”
Volv Global sits at the crucial intersection between technology and human beings, i.e., patients and physicians, supporting favourable patient journeys and outcomes. We use each World Orphan Drug Congress as our touchpoint with the rare disease community, in particular as an opportunity to learn and share with everyone in rare disease, from patients and patient advocacy organisations, to physicians and healthcare providers, to pharma companies, to policy makers and regulators.
Meet us at the World Orphan Drug Congress Europe 2025 in Amsterdam, 27th-29th October, to find out more:
🟥 Volv Global panel: “Bridging the unbridgeable: clinical expertise vs. real-world data” (Clinical Development track)
- Our own panel on making better use of real-world data, leveraging novel computer data-science methods like machine learning to ultimately generate natural history studies. Looking forward to a stimulating, inspiring and action-oriented session, supported by a wider group of stakeholder parties, including current initiatives ongoing in the area of patient journey & experience, to map out where patients incur diagnosis delays, and inform various aspects of clinical development and care optimisation.
- 12:15-12:45, Wednesday, 29th October.
- Speakers: tba.
🟥 Christopher Rudolf, Founder and Chief Executive Officer, Volv Global, will be on two keynote panels:
🟥 Patient Centricity Panel: Driving Patient-Centric Innovation: Pharma’s Involvement and Stakeholder Collaboration” – 16.50 on Tuesday, 28th October.
🟥 Keynote panel: “Leveraging new technology for smarter decision-making in Rare Disease drug development and access.” – 09.00 on Wednesday, 29th October.
🟥 Our booth: #10.301
As a Gold Sponsor, Volv Global has a number of discounted tickets for our clients and partners – do contact us if you need a ticket.
Looking forward to having great discussions with you there – please Contact Us to book a meeting!
Rewind to last year’s event: at Volv Global, we use each World Orphan Drug Congress as our touchpoint with the rare disease community, in particular as an opportunity to learn and share with everyone in rare disease, from patients and patient advocacy organisations, to physicians and healthcare providers, to pharma companies, to policy makers and regulators. As we gear up for WODC Europe 2025, here’s a look back at last year’s, in Barcelona, where we ran a workshop on creating real impact for rare disease patients together with participants representing patients and physicians, healthcare providers and healthcare authorities: Our journey to solving complexity throughout the healthcare ecosystem to create real impact for rare disease patients
Link to WODC EU 2025: World Orphan Drug Congress 2025 | Amsterdam
